亨鑫科技(01085.HK)主要股東及董事Kingever向Wellahead購買1200萬股公司股份
格隆匯4月27日丨亨鑫科技(01085.HK)發佈公吿,公司主要股東及董事Kingever Enterprises Limited知會公司,其於2021年4月26日從Wellahead以每股港元2.20購買1200萬股公司股份。
緊隨出售及購買後及於本公吿日期,Kingever現持有1.09億股股份,相當於公司已發行股份總數約28.06%,而Wellahead現持有1608萬股股份,相當於公司已發行股份總數約4.14%。
公司董事會認為於公司增持表示主要股東作出的長期承諾以及對公司未來發展有信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.